U.S. Court Ban On Federal Funding For Embryonic Stem Cell Research Would Help China In Race To Lead The Field
This article was originally published in PharmAsia News
Executive Summary
BEIJING - If a court battle now being waged in the American federal judiciary over embryonic stem cell research ends with a new ban on U.S. government funding for these studies, the freeze would give China a boost in its race to become a dominant power in this field, according to a scholar who tracks stem cell research on both sides of the Pacific
You may also be interested in...
Head Of U.S. National Institutes Of Health Warns Court Ban On Funding For Embryonic Stem Cell Research Could Trigger Flight Of Best Scientists To Rival Centers Abroad
BEIJING - As lawyers for the United States Department of Justice and for those seeking to halt all federal funding for embryonic stem cell research prepare for a new round of battle in a U.S. Court of Appeals, the head of the National Institutes of Health is warning that a funding freeze could trigger an exodus of the best embryonic stem cell scientists to rival centers abroad
China Emerging As World Power In Stem Cell Research
BEIJING - China is speedily evolving into a global power in terms of stem cell research, with the central government stepping up funding and recruiting scientists worldwide in order to catapult the country into the advance ranks of regenerative medicine, according to four scholars at the University of Toronto
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).